Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Accrued expenses Accrued Liabilities, Current Statistical Measurement Statistical Measurement [Domain] Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Equity Award Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Other cost Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Commitments and contingencies (Note 8) Commitments and Contingencies Measurement Input, Price Volatility Measurement Input, Price Volatility [Member] Insider Trading Policies and Procedures [Line Items] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Shares issued (in usd per share) Shares Issued, Price Per Share Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Amended and Restated 2014 Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan Milestone payments, contingent amount Milestone Payments, Contingent Amount Milestone payments, contingent amount. Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Aggregate net proceeds on sales of shares of common stock Proceeds from Issuance of Common Stock Options exercisable, ending (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Grant Date Fair Value Other non-current assets Increase (Decrease) in Other Noncurrent Assets Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Pear Tree Pharmaceuticals, Inc. Pear Tree Pharmaceuticals, Inc. [Member] Pear Tree Pharmaceuticals, Inc. Restricted cash included in other non-current assets Restricted Cash and Cash Equivalents, Noncurrent Project [Domain] Project [Domain] Current liabilities Liabilities, Current [Abstract] March 2023 At The Market Sales Agreement March 2023 At The Market Sales Agreement [Member] March 2023 At The Market Sales Agreement Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding Preferred Stock, Value, Issued Subsequent Event Type Subsequent Event Type [Domain] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Loss per common share - diluted (in usd per share) Earnings Per Share, Diluted Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] PEO Total Compensation Amount PEO Total Compensation Amount Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Grant, DARE-PTB1 Grant, DARE-PTB1 [Member] Grant, DARE-PTB1 Stock options outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Interest rate on insurance financing Insurance Financing, Interest Rate Insurance Financing, Interest Rate Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leased Properties Lessee, Operating Leases [Text Block] Liabilities and stockholders’ equity (deficit) Liabilities and Equity [Abstract] Stockholders' equity (deficit) Equity, Attributable to Parent [Abstract] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Executive Category: Executive Category [Axis] Deposits Deposits Assets, Noncurrent Proceeds from award of grants Proceeds From Award Of Grants Proceeds From Award Of Grants Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Issuance of common stock from the exercise of warrants Adjustments to Additional Paid in Capital, Warrant Issued Equity Components [Axis] Equity Components [Axis] Exercise Price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses Increase (Decrease) in Accrued Liabilities Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Measurement Basis [Axis] Measurement Basis [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Measurement Frequency [Axis] Measurement Frequency [Axis] Warrants Warrant [Member] Lease liabilities long-term Operating Lease, Liability, Noncurrent Royalties payable Increase (Decrease) in Royalties Payable Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Class of Warrant or Right [Table] Class of Warrant or Right [Table] Depreciation Depreciation Total payment Research and Development Agreement, Commitment, Amount Research and Development Agreement, Commitment, Amount Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Net proceeds from issuance of common stock Net Proceeds From Issuance Of Common Stock And Warrants Net proceeds from issuance of common stock and warrants. Income Statement Location Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Additional investment amount Class Of Warrant Or Right, Supplement Investment Class Of Warrant Or Right, Supplement Investment Outstanding and exercisable, Weighed Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Remaining Contractual Terms Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding And Exercisable, Weighted Average Remaining Contractual Terms Going Concern Going Concern [Policy Text Block] Going Concern Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Foundation Foundation [Member] Foundation Biotherapeutic Product Grant Agreement Biotherapeutic Product Grant Agreement [Member] Biotherapeutic Product Grant Agreement Class of warrant or right, extent holder own percentage Class of Warrant or Right, Extent Holder Own Percentage Class of Warrant or Right, Extent Holder Own Percentage Number of significant performance obligations Revenue, Number Of Significant Performance Obligations Revenue, Number Of Significant Performance Obligations Sale of stock, number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Commission percent Percentage Of Aggregate Commission Percentage of aggregate commission. Total revenue Revenues Measurement Input, Risk Free Interest Rate Measurement Input, Risk Free Interest Rate [Member] Product and Service [Domain] Product and Service [Domain] Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Class of warrant or right, exercises Class Of Warrant Or Right, Exercises Class Of Warrant Or Right, Exercises Research and development Research and Development Expense [Member] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] CRADA CRADA [Member] CRADA Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type Award Type [Axis] Plan Name Plan Name [Domain] Document Quarterly Report Document Quarterly Report Royalty Purchase Agreement Royalty Purchase Agreement [Member] Royalty Purchase Agreement Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] General and administrative General and Administrative Expense [Member] Options to purchase number of outstanding shares of common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Operating right-of-use assets obtained in exchange for new operating lease liabilities, net Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Royalty payments Payments for Royalties Trading Arrangement: Trading Arrangement [Axis] Less: accreted interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Number of additional payment Royalty Agreement, Number Of Additional Payments Royalty Agreement, Number Of Additional Payments Class of warrant or right, extent holder own percentage Class of Warrant or Right, Holder Election Percentage Class of Warrant or Right, Holder Election Percentage Current portion of lease liabilities Operating Lease, Liability, Current Prepaid expenses Prepaid Expense, Current Sales based milestones amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Advanced written notice period Upfront License Fee, Advanced Written Notice, Period Upfront License Fee, Advanced Written Notice, Period Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Restatement Determination Date Restatement Determination Date Bayer Bayer Healthcare LLC [Member] Bayer Healthcare LLC Prepaid expenses Increase (Decrease) in Prepaid Expense Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Outstanding and exercisable (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Outstanding And Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Outstanding And Exercisable Measurement Input, Expected Term Measurement Input, Expected Term [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Non-cash lease expenses Operating Lease, Cost Common stock, shares issued (in shares) Common Stock, Shares, Issued Credits to research and development expense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Shares of common stock for net proceeds Sale of Stock, Consideration Received on Transaction Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Strategic Agreements Collaborative Arrangement Disclosure [Text Block] Employee Stock Option Stock options Employee Stock Option [Member] Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Initial payment Grants Receivable Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Non-cash interest expense on liability related to sale of future royalties Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties Subsequent Event [Table] Subsequent Event [Table] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Business Acquisition Business Acquisition [Axis] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Subsequent Event Subsequent Event [Member] Merger Agreement Merger Agreement [Member] Merger Agreement Premiums, taxes and fees Insurance Financing, Premiums, Taxes And Fees, Amount Insurance Financing, Premiums, Taxes And Fees, Amount Income Statement [Abstract] Income Statement [Abstract] Canceled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Number of experts License Agreement, Number Of Experts License Agreement, Number Of Experts Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Related Party Related Party, Type [Domain] Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Class of warrant or right, number of securities called by each warrant or right Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Working capital Working Capital Increase (Deficit) Working Capital Increase (Deficit) Future net sales Royalty Agreement, Future Net Sales, Percentage Royalty Agreement, Future Net Sales, Percentage Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Other current assets Other Assets, Current Expiration period License Agreement, Expiration Period License Agreement, Expiration Period Class of Stock [Line Items] Class of Stock [Line Items] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Milestone payments, reimburse amount, PDUFA fees and other manufacturing expenses Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses Repayment of liability on sale of future royalties Repayment Of Liability On Sale Future Royalties Repayment Of Liability On Sale Future Royalties Statistical Measurement Statistical Measurement [Axis] Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Other current assets Increase (Decrease) in Other Current Assets Entity Interactive Data Current Entity Interactive Data Current Supplemental investment (in shares) Class Of Warrant Or Right, Supplement Investment Share Amount Class Of Warrant Or Right, Supplement Investment Share Amount 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Liability related to the sale of future royalties, net Royalty Guarantees, Commitments, Amount Total Shareholder Return Amount Total Shareholder Return Amount Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the consolidated balance sheets: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] XOMA XOMA (US) LLC [Member] XOMA (US) LLC Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Weighted average amortization period Weighted Average Amortization Period Weighted Average Amortization Period Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Class of Warrant or Right Class of Warrant or Right [Domain] Interest payable Increase (Decrease) in Interest Payable, Net Cash paid for measurement of operating lease liabilities Operating Lease, Payments Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Other cost and expense Other Cost and Expense, Operating Maximum royalty payments Royalty Agreement, Maximum Royalty Payments Royalty Agreement, Maximum Royalty Payments Milestone payments Research And Development Milestone Payment Research and development milestone payment. Deferred grant funding Deferred Grant Funding Current Deferred Grant Funding Current Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Sale of Stock Sale of Stock [Axis] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities DARE-LARC1 2021 Grant Agreement DARE-LARC1 2021 Grant Agreement [Member] DARE-LARC1 2021 Grant Agreement Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Collaborative Arrangement Collaborative Arrangement [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Total operating lease liabilities Operating Lease, Liability Measurement Input Type [Domain] Measurement Input Type [Domain] Total liabilities Liabilities Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Deferred revenue, non-current Contract with Customer, Liability, Noncurrent Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name Plan Name [Axis] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. License fee expense License Fee Expense License Fee Expense Related Party Transaction [Domain] Related Party Transaction [Domain] Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Number of Shares Underlying Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Common stock, $0.0001 par value; 240,000,000 shares authorized; 100,581,900 and 99,973,932 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Sildenafil Cream, 3.6% Sildenafil Cream, 3.6% [Member] Sildenafil Cream, 3.6% All Individuals All Individuals [Member] Supplemental disclosure of non-cash investing and financing activities: Supplemental Cash Flow Information [Abstract] Quarterly payment period Royalty Agreement, Quarterly Payments, Period Royalty Agreement, Quarterly Payments, Period Other income (expense) Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category DARE-LARC1 DARE-LARC1 [Member] DARE-LARC1 Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date PEO Name PEO Name Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Incremental borrowing rate, amount over prime rate Operating Lease, Incremental Borrowing Rate, Prime Rate Operating Lease, Incremental Borrowing Rate, Prime Rate Internal rate of return Royalty Agreement, Internal Rate Of Return Royalty Agreement, Internal Rate Of Return Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Royalties payable Royalties Payable, Current Royalties Payable, Current Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Right of use asset - operating lease Increase (Decrease) In Operating Lease Right-of-Use Asset Increase (Decrease) In Operating Lease Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] United in Endeavor, LLC United in Endeavor, LLC [Member] United in Endeavor, LLC Measurement Input, Expected Dividend Payment Measurement Input, Expected Dividend Payment [Member] Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Outstanding and exercisable, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding And Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding And Exercisable Registered Direct Offering Registered Direct Offering [Member] Registered Direct Offering Total stockholders' equity (deficit) Beginning balance Ending balance Equity, Attributable to Parent Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Percentage of royalty rate Royalty Rate, Percentage Royalty Rate, Percentage Proceeds from the exercise of common stock warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Phase II Segment Phase II Segment [Member] Phase II Segment Subsequent Events [Abstract] Subsequent Events [Abstract] MBI MBI [Member] MBI Warrants and rights outstanding, measurement input Warrants and Rights Outstanding, Measurement Input Catalent and MilanaPharm Catalent and MilanaPharm [Member] Catalent and MilanaPharm Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Debt issuance cost Debt Issuance Costs, Net Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Milestone payment revenues Milestone Payment Revenues Milestone Payment Revenues 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities Antidilutive Securities [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Title Trading Arrangement, Individual Title Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Potential future payment Royalty Agreement, Maximum Potential Milestone Payments Royalty Agreement, Maximum Potential Milestone Payments Common stock Common stock Common Stock [Member] Warrant, exercise price, decrease (in usd per share) Warrant, Exercise Price, Decrease Individual: Individual [Axis] Licensed Product or Process for Vaginal or Urological Use Licensed Product or Process for Vaginal or Urological Use [Member] Licensed Product or Process for Vaginal or Urological Use Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Product and Service [Axis] Product and Service [Axis] Net Loss Per Share Earnings Per Share [Text Block] Royalty revenue Royalty [Member] Income Statement Location Income Statement Location [Domain] Sale of stock, prospectus offering amount Sale Of Stock, Prospectus Offering Amount Sale Of Stock, Prospectus Offering Amount Document Fiscal Year Focus Document Fiscal Year Focus Weighted Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Minimum Minimum [Member] Weighted average number of shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property, Plant and Equipment, Net Receivables [Abstract] Receivables [Abstract] Summary of Stock Option Activity for Amended 2014 Plan and Related Information Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] 2022 Stock Incentive Plan Two Thousand Twenty Two Stock Incentive Plan [Member] Two Thousand Twenty Two Stock Incentive Plan Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Juniper Pharmaceuticals, Inc Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Potential future payment, percentage Royalty Agreement, Milestone Payments, Sales Based Potential Future Milestones Royalty Agreement, Milestone Payments, Sales Based Potential Future Milestones Operating lease liability Increase (Decrease) in Operating Lease Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Accounts payable Increase (Decrease) in Other Accounts Payable Accumulated deficit Retained Earnings [Member] Cash paid to stockholders' representative Payments to Stockholders' Representative in Business Combination Payments to Stockholders' Representative in Business Combination Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders' equity (deficit) Liabilities and Equity Revenue tier threshold, upper range limit Royalty Agreement, Revenue Tier Threshold, Incremental Amount Royalty Agreement, Revenue Tier Threshold, Incremental Amount Other non-current assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Loss per common share - basic (in usd per share) Earnings Per Share, Basic Operating lease right-of-use assets Right of use asset Operating Lease, Right-of-Use Asset Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Grant, ADARE-204 and ADARE-214 Grant, ADARE-204 and ADARE-214 [Member] Grant, ADARE-204 and ADARE-214 Sale of Stock Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Warrant term Warrants and Rights Outstanding, Term Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current Remainder of 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Royalty Investment Financing Agreement Royalty Investment Financing Agreement [Member] Royalty Investment Financing Agreement Arrangement Duration Trading Arrangement Duration License And Collaboration Revenue License And Collaboration Revenue [Member] License And Collaboration Revenue Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Sale Of Future Royalties Sale Of Future Royalties [Text Block] Sale Of Future Royalties Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Royalty Revenue Royalty Revenue [Member] Royalty Revenue Contingent purchase price payments Royalty Agreement, Contingent Purchase Price Payments Royalty Agreement, Contingent Purchase Price Payments Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Hard cap rate Royalty Agreement, Hard Cap, Percentage Royalty Agreement, Hard Cap, Percentage Issuable upon additional investment made number of securities called by warrants Class Of Warrant Or Right, Initial Royalty Warrant Issued Class Of Warrant Or Right, Initial Royalty Warrant Issued Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] All Adjustments to Compensation All Adjustments to Compensation [Member] Milestone payments rate Royalty Agreement, Milestone Payments, Percentage Royalty Agreement, Milestone Payments, Percentage Award Timing Disclosures [Line Items] Cash and Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Exercised (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value Annual percentage increase in outstanding number of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Compensation Amount Outstanding Recovery Compensation Amount Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Royalty expense Royalty Expense Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] DARE-LBT DARE-LBT [Member] DARE-LBT Subsequent Event Type Subsequent Event Type [Axis] Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Other receivables Increase (Decrease) in Other Receivables Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Canceled/forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Common stock issued to microchips capital stock holders (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Insider Trading Arrangements [Line Items] Ovaprene Ovaprene [Member] Ovaprene Related Party Related Party, Type [Axis] Forfeited or expired (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Upfront license fee paid Upfront License Fee, Amount Paid Upfront License Fee, Amount Paid Warrants and rights outstanding (in shares) Relative fair value of Initial Royalty Warrant Warrants and Rights Outstanding Adjustment to Compensation, Amount Adjustment to Compensation Amount Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Unamortized stock-based compensation expense Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent Exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Net royalty payments rate Royalty Agreement, Net Royalty Payments, Percentage Royalty Agreement, Net Royalty Payments, Percentage Entity Central Index Key Entity Central Index Key Class of Warrant or Right Class of Warrant or Right [Axis] Supplemental investment payment Royalty Agreement, Supplement Investment Payment Royalty Agreement, Supplement Investment Payment Disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Outstanding, Weighed Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Grant, DARE-PTB2 Grant, DARE-PTB2 [Member] Grant, DARE-PTB2 Proceeds from royalties received Upfront payment from the sale of future royalties Proceeds from Royalties Received Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Hennepin License Agreement Hennepin License Agreement [Member] Hennepin License Agreement Grant Awards Grant Award [Text Block] Grant Award [Text Block] NICHD NICHD [Member] NICHD Equity [Abstract] Equity [Abstract] Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term First commercial sale amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Total revenue License and collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Other receivables Other Receivables, Net, Current Entity Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Schedule of Changes in the Liability Related to the Sale of Future Royalties Schedule Of Changes In The Liability Related To The Sale Of Future Royalties [Table Text Block] Schedule Of Changes In The Liability Related To The Sale Of Future Royalties Square footage of office space Net Rentable Area Amendment Flag Amendment Flag Legal Entity Legal Entity [Axis] Phase I Segment Phase I Segment [Member] Phase I Segment Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Payments on note payable Repayments of Notes Payable Weighted average interest rate Operating Lease, Weighted Average Discount Rate, Percent Licensing Agreements Licensing Agreements [Member] Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Warrants Warrants [Member] Warrants Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Operating expenses Operating Expenses [Abstract] XACIATO XACIATO [Member] XACIATO Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid-in Capital [Member] Estimated fair value of warrants recorded in equity Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Expired (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Commitments and Contingencies Commitments Disclosure [Text Block] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Cover [Abstract] Subsequent Events Subsequent Events [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Non-NEOs Non-NEOs [Member] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Increase in number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Number of Shares, Period Increase (Decrease) Total operating expenses Operating Expenses Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Renewal term of operating lease Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Project [Axis] Project [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Loss from operations Operating Income (Loss) ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Revenue Revenues [Abstract] Douglas License Agreement Douglas License Agreement [Member] Douglas License Agreement Issuance of common stock from the exercise of warrants (in shares) Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Effective annual interest rate Royalty Agreement, Effective Annual Interest Rate, Percentage Royalty Agreement, Effective Annual Interest Rate, Percentage Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Organon Organon [Member] Organon Deposits Increase (Decrease) in Deposit Assets Payment of additional consideration Payment of Additional Consideration in Business Combination Payment of Additional Consideration in Business Combination License [Member]